Cellectar Biosciences (NV40) Q2 2026 Earnings Report

The call conveyed strong clinical validation for iopofosine (durable responses and high response rates including a near-80% major response in the BTKi-exposed subgroup), clear progress toward a confirmatory Phase III and an intended accelerated approval filing in 1H 2027, plus meaningful balance-sheet reinforcement from an oversubscribed financing. The company is also advancing CLR 125 and expanding its PDC platform with supporting peer-reviewed data and manufacturing readiness. Offsetting these positives are materially higher R&D costs, a wider net loss in dollar terms, timing and operational risks tied to site activation/IRB/radiopharmacy readiness, just-in-time isotope production complexities, actinium-225 supply risk for alpha programs, and potential dilution from issued warrants. Overall, the highlights (clinical data, regulatory path, financing, pipeline expansion and manufacturing preparedness) materially outweigh the operational and financing caveats.

Management guided that site activation for the confirmatory Phase III of iopofosine I‑131 is underway with first sites expected to open in the coming months and first patient dosing possible late 2026 or early 2027, targeting an accelerated‑approval submission in H1/mid‑2027 (management also referenced a March–April timeframe) with an anticipated ~6‑month FDA review under Breakthrough designation; they expect roughly 10–20 sites open at submission, a couple of patients enrolled by submission and ~5%+ of patients enrolled by the time of regulatory action (6–8 months after submission). Key clinical metrics cited: CLOVER‑WaM BTKi‑immediate subgroup showed a 79.2% major response rate, 87.5% overall response rate, 100% clinical benefit rate and median duration of response (DOR) ~16 months; the full 12‑month dataset showed median DOR 17.8 months, ~62% major response and VGPR+CR of 14.5% in late‑line patients. Financial and capital metrics: May financing up to $140M (including $35M upfront, ~$31.7M net, plus up to $105M tied to milestones); three warrant tranches (~13.2M each) exercisable at $2.65 (expiries 7/7/2027, 7/7/2028, 7/7/2031) with tranche milestones (A=first patient enrolled, B=NDA acceptance, C=FDA approval) and callable only if VWAP ≥ $3.45 and VWAP liquidity ≥ $500k for 20 consecutive trading days; cash $34.0M at 6/30/26 (vs $13.2M at 12/31/25). Q2 operating metrics: R&D $4.6M (Q2 2026) vs $2.4M (Q2 2025), G&A $2.6M vs $3.6M, net loss $6.9M or $0.57/share vs $5.4M or $3.39/share. Operational/pipeline notes: ligand inventory has >5 years stability, finished‑product capacity cited at ~100 patients/week (company also referenced capacity approaching ~1,000 patient scale), CLR‑125 Phase Ib has dosed first patients with initial dosimetry/safety/efficacy data expected late 2026 or early 2027, and an educational webinar was scheduled for Aug 18.